Same gain, less pain: Potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer

European Journal of Cancer

Volumn 40, Issue 16, 2004, Pages 2403-2410

  Fallowfield, Lesley ^a   McGurk, Rhona ^a   Dixon, Michael ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

CMF; Early breast cancer; ER+; Goserelin; Patient choice; Pre menopausal

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CONSTIPATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFECT; DRUG INFORMATION; DRUG PREFERENCE; FATIGUE; FEMALE; FERTILITY; FLUID RETENTION; FLUSHING; HAIR LOSS; HUMAN; HYPOTHESIS; IMMUNE DEFICIENCY; MEMORY DISORDER; MENSTRUAL IRREGULARITY; MOOD; MOUTH ULCER; NAUSEA; NIGHT SWEAT; PREMENOPAUSE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SIDE EFFECT; VAGINAL DRYNESS; VOMITING; WEIGHT GAIN;

ACTIVITIES OF DAILY LIVING; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FERTILITY; FLUOROURACIL; GOSERELIN; HUMANS; INTERPERSONAL RELATIONS; METHOTREXATE; MIDDLE AGED; PATIENT SATISFACTION; PREMENOPAUSE; TIME FACTORS;

EID: 7044238403     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.07.013     Document Type: Article

References (30)

1. Scottish Cancer Trials Breast Group and ICRF Breast Unit GsH. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993, 341 (8856), 1293-98
2. Roche H, Kerbrat P, Bonneterre J, Fargeot P, Fumoleau P, Monnier A, et al. Complete Hormonal, Blockade Versus Chemotherapy in Premenopausal Early-Stage Breast Cancer Patients (Pts) with Positive Hormone-Receptor (HR+) and 1-3 Node-Positive (N+) Tumor: results of the FASG 06 Trial. In Proceedings of the American Society of Clinical Oncology, 2000, p. 279 (abstract)
3. R. Sainsbury Ovarian ablation in the adjuvant treatment of premenopausal and perimenopausal breast cancer Brit. J. Surg. 90 5 2003 517 526
4. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000, 18(14), 2718-27. Available from: boccardo@hp380.ist.unige.it
5. W. Jonat, M. Kaufmann, W. Sauerbrei, R. Blamey, J. Cuzick, and M. Namer Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study J. Clin. Oncol. 20 24 2002 4628 4635
6. M. Kaufmann, W. Jonat, R. Blamey, J. Cuzick, M. Namer, and I. Fogelman Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer Eur. J. Cancer 39 12 2003 1711 1717
7. R. Jakesz, H. Hausmaninger, and H. Samonigg Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer Eur. J. Cancer 38 3 2002 327 332
8. Davidson NE, O'Neill A, Vukov A, Osborne CK, Martino S, White D, et al. Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188,INT-0101). In ASCO, 2003
9. R. Jakesz, H. Hausmaninger, E. Kubista, M. Gnant, C. Menzel, and T. Bauernhofer Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5 J. Clin. Oncol. 20 24 2002 4621 4627
10. D. Fellowes, L.J. Fallowfield, C.M. Saunders, and J. Houghton Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Res. Tr. 66 1 2001 73 81
11. M. Nystedt, G. Berglund, C. Bolund, T. Fornander, and L.E. Rutqvist Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study J. Clin. Oncol. 21 9 2003 1836 1844
12. H. De Haes, M. Olschewski, M. Kaufmann, M. Schumacher, W. Jonat, and W. Sauerbrei Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil - treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the zoladex early breast cancer research association trialists group J. Clin. Oncol. 21 24 2003 4510 4516
13. C. Hurny, J. Bernhard, and A. Coates Quality of life assessment in the International Breast Cancer Study Group: past, present, and future Recent Res. Cancer Res. 152 1998 390 395
14. W. Jonat Goserelin (Zoladex) - its role in early breast cancer in pre- and perimenopausal women Brit. J. Cancer 85 Suppl. 2 2001 1 5
15. K.I. Pritchard Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift? J. Clin. Oncol. 20 24 2002 4611 4614
16. L. Fallowfield Participation of patients in decisions about treatment for cancer BMJ 323 7322 2001 1144
17. P.J. Goodwin Reversible ovarian ablation or chemotherapy: are we ready for quality of life to guide adjuvant treatment decisions in breast cancer J. Clin. Oncol. 21 24 2003 4474 4475
18. L.J. Fallowfield, A. Hall, P. Maguire, M. Baum, and R.P. A'Hern A question of choice: results of a prospective 3-year follow-up study of women with breast cancer Breast 3 1994 202 208
19. S. Turner, E.J. Maher, T. Young, J. Young, and G. Vaughan Hudson What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease Brit. J. Cancer 73 2 1996 222 227
20. A. Coulter, V. Entwistle, and D. Gilbert Sharing decisions with patients: is the information good enough BMJ 318 7179 1999 318 322
21. V. Carstairs Deprivation indices: their interpretation and use in relation to health J. Epidemiol. Commun. H. 49 Suppl. 2 1995 S3 S8
22. Cancer Research UK. Breast Cancer Factsheet, 1998. Available from: http://www.cancerresearchuk. org/aboutcancer/statistics/factsheets/
23. Office for National Statistics. South East Region in Figures. Vol 6 ed; 2002. Available from: http://www.statistics.gov.uk/downloads/theme_compendia/ region_in_figures
24. Office for National Statistics. Cancer Trends in England and Wales 1950-1999, 2000, Available from: http://www.statistics.gov. uk/downloads/ theme_health/cancertrends_5099.pdf
25. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352(9132), 930-42
26. P. Katsimbri, A. Bamias, and N. Pavlidis Prevention of chemotherapy-induced alopecia using an effective scalp cooling system Eur. J. Cancer 36 6 2000 766 771
27. C. Christodoulou, G. Klouvas, E. Efstathiou, D. Zervakis, E. Papazachariou, and M. Plyta Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia Oncology 62 2 2002 97 102
28. P. Eifel, J.A. Axelson, J. Costa, J. Crowley, W.J. Curran Jr., and A. Deshler National Institutes of Health Consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000 J. Natl. Cancer I. 93 13 2001 979 989
29. A. Goldhirsch, W.C. Wood, R.D. Gelber, A.S. Coates, B. Thurlimann, and H.J. Senn Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer J. Clin. Oncol. 21 17 2003 3357 3365
30. R.W. Blamey Guidelines on endocrine therapy of breast cancer EUSOMA Eur. J. Cancer 38 5 2002 615 634